Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 42.72
(0.73%)
INR 42.72
(0.73%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 14.57 Million INR | -31.82% |
| 2022 | 21.38 Million INR | -14.7% |
| 2021 | 25.07 Million INR | -24.56% |
| 2020 | 33.23 Million INR | -24.15% |
| 2019 | 43.81 Million INR | 39.71% |
| 2018 | 31.36 Million INR | 21.14% |
| 2017 | 25.88 Million INR | -47.63% |
| 2016 | 49.43 Million INR | 175.59% |
| 2015 | 17.93 Million INR | 21.63% |
| 2014 | 14.74 Million INR | -22.07% |
| 2013 | 18.92 Million INR | 9.64% |
| 2012 | 17.25 Million INR | 69.52% |
| 2011 | 10.18 Million INR | 443.8% |
| 2010 | 1.87 Million INR | 53.46% |
| 2009 | 1.22 Million INR | -65.55% |
| 2008 | 3.54 Million INR | 23.18% |
| 2007 | 2.87 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.9 Million INR | 154.2% |
| 2023 Q1 | 7.03 Million INR | 1.48% |
| 2023 Q3 | 5.68 Million INR | 12.08% |
| 2023 Q4 | 1.93 Million INR | -66.06% |
| 2023 FY | 14.57 Million INR | -31.82% |
| 2023 Q2 | 5.07 Million INR | -27.92% |
| 2022 Q2 | 3.75 Million INR | -42.06% |
| 2022 FY | 21.38 Million INR | -14.7% |
| 2022 Q4 | 6.93 Million INR | 64.06% |
| 2022 Q3 | 4.22 Million INR | 12.75% |
| 2022 Q1 | 6.47 Million INR | -31.75% |
| 2021 Q1 | 6.31 Million INR | -22.82% |
| 2021 FY | 25.07 Million INR | -24.56% |
| 2021 Q3 | 7.29 Million INR | 15.37% |
| 2021 Q2 | 6.32 Million INR | 0.14% |
| 2021 Q4 | 9.48 Million INR | 29.96% |
| 2020 Q4 | 8.18 Million INR | -14.35% |
| 2020 Q2 | 13.49 Million INR | 4842.49% |
| 2020 Q3 | 9.55 Million INR | -29.19% |
| 2020 FY | 33.23 Million INR | -24.15% |
| 2020 Q1 | 273 Thousand INR | -98.08% |
| 2019 Q4 | 14.25 Million INR | 70.84% |
| 2019 FY | 43.81 Million INR | 39.71% |
| 2019 Q1 | 6.16 Million INR | -42.37% |
| 2019 Q2 | 15.04 Million INR | 144.05% |
| 2019 Q3 | 8.34 Million INR | -44.55% |
| 2018 Q4 | 10.7 Million INR | 29.09% |
| 2018 FY | 31.36 Million INR | 21.14% |
| 2018 Q1 | 5.63 Million INR | -54.56% |
| 2018 Q2 | 6.73 Million INR | 19.46% |
| 2018 Q3 | 8.28 Million INR | 23.11% |
| 2017 Q3 | 6.32 Million INR | 56.98% |
| 2017 Q1 | 3.12 Million INR | -87.41% |
| 2017 Q2 | 4.03 Million INR | 28.87% |
| 2017 FY | 25.88 Million INR | -47.63% |
| 2017 Q4 | 12.4 Million INR | 95.99% |
| 2016 Q3 | 12.56 Million INR | 26.0% |
| 2016 Q2 | 9.97 Million INR | 349.53% |
| 2016 Q1 | 2.21 Million INR | -88.19% |
| 2016 Q4 | 24.84 Million INR | 97.7% |
| 2016 FY | 49.43 Million INR | 175.59% |
| 2015 FY | 17.93 Million INR | 21.63% |
| 2015 Q3 | 4.67 Million INR | 115.15% |
| 2015 Q1 | 2.65 Million INR | -54.93% |
| 2015 Q2 | 2.17 Million INR | -18.04% |
| 2015 Q4 | 18.79 Million INR | 302.1% |
| 2014 Q2 | 3.82 Million INR | 178.66% |
| 2014 Q4 | 5.87 Million INR | 91.65% |
| 2014 FY | 14.74 Million INR | -22.07% |
| 2014 Q3 | 3.06 Million INR | -19.81% |
| 2014 Q1 | 1.37 Million INR | 13.5% |
| 2013 Q3 | 13.05 Million INR | 493.05% |
| 2013 Q1 | 2.45 Million INR | -78.56% |
| 2013 FY | 18.92 Million INR | 9.64% |
| 2013 Q2 | 2.2 Million INR | -10.23% |
| 2013 Q4 | 1.2 Million INR | -90.74% |
| 2012 Q1 | 2.42 Million INR | 267.22% |
| 2012 Q4 | 11.44 Million INR | 609.28% |
| 2012 FY | 17.25 Million INR | 69.52% |
| 2012 Q3 | 1.61 Million INR | -9.48% |
| 2012 Q2 | 1.78 Million INR | -26.49% |
| 2011 FY | 10.18 Million INR | 443.8% |
| 2011 Q4 | -1.44 Million INR | -170.47% |
| 2011 Q3 | 2.05 Million INR | 0.0% |
| 2010 FY | 1.87 Million INR | 53.46% |
| 2009 FY | 1.22 Million INR | -65.55% |
| 2008 FY | 3.54 Million INR | 23.18% |
| 2008 Q4 | 2.37 Million INR | 0.0% |
| 2007 FY | 2.87 Million INR | 0.0% |
| 2007 Q4 | 1.73 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 99.946% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.991% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 99.883% |
| Granules India Limited | 16.79 Billion INR | 99.913% |
| Indoco Remedies Limited | 6.04 Billion INR | 99.759% |
| Achyut Healthcare Limited | 4.86 Million INR | -199.932% |
| Ajanta Pharma Limited | 21.06 Billion INR | 99.931% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.972% |
| Alpa Laboratories Limited | 188.89 Million INR | 92.282% |
| Brooks Laboratories Limited | 65.62 Million INR | 77.782% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 99.766% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 99.009% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 99.605% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.991% |
| Eris Lifesciences Limited | 10.42 Billion INR | 99.86% |
| FDC Limited | 8.33 Billion INR | 99.825% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.979% |
| Gufic Biosciences Limited | 4.16 Billion INR | 99.65% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 99.765% |
| Ipca Laboratories Limited | 29.8 Billion INR | 99.951% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 97.766% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | 92.435% |
| Lasa Supergenerics Limited | 121.02 Million INR | 87.954% |
| Laurus Labs Limited | 24.62 Billion INR | 99.941% |
| Lupin Limited | 123.71 Billion INR | 99.988% |
| Mankind Pharma Limited | 44.52 Billion INR | 99.967% |
| Medicamen Biotech Limited | 495.49 Million INR | 97.058% |
| Medico Remedies Limited | 262.14 Million INR | 94.438% |
| Megasoft Limited | 342.07 Million INR | 95.738% |
| NATCO Pharma Limited | 25.73 Billion INR | 99.943% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.94% |
| RPG Life Sciences Limited | 2.48 Billion INR | 99.413% |
| Sigachi Industries Limited | 2 Billion INR | 99.272% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.994% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 99.646% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 98.453% |
| Unichem Laboratories Limited | 4.86 Billion INR | 99.7% |
| Wanbury Limited | 1.73 Billion INR | 99.158% |
| Windlas Biotech Limited | 1.33 Billion INR | 98.911% |
| ZIM Laboratories Limited | 1.26 Billion INR | 98.849% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.988% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 102.42% |
| Divi's Laboratories Limited | 32.44 Billion INR | 99.955% |
| Hester Biosciences Limited | 1.27 Billion INR | 98.855% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 99.748% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 99.063% |
| Bal Pharma Limited | 770.19 Million INR | 98.107% |
| Strides Pharma Science Limited | 14.38 Billion INR | 99.899% |
| Venus Remedies Limited | 2.18 Billion INR | 99.332% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 99.75% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 99.509% |
| Shilpa Medicare Limited | 3.54 Billion INR | 99.589% |
| Aarti Drugs Limited | 8.31 Billion INR | 99.825% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 99.682% |
| Suven Life Sciences Limited | -200.79 Million INR | 107.261% |
| Ind-Swift Limited | 2.17 Billion INR | 99.329% |
| Valiant Laboratories Limited | -60.66 Million INR | 124.034% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 99.936% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 98.307% |
| Themis Medicare Limited | 1.5 Billion INR | 99.031% |
| Hikal Limited | 3.14 Billion INR | 99.536% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.969% |
| Sequent Scientific Limited | 2.97 Billion INR | 99.511% |
| Novartis India Limited | 1.32 Billion INR | 98.901% |
| Wockhardt Limited | 16.24 Billion INR | 99.91% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 99.926% |
| Neuland Laboratories Limited | 8.24 Billion INR | 99.823% |
| Morepen Laboratories Limited | 6.16 Billion INR | 99.763% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 97.65% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 97.928% |